Retatrutide Bulk Sourcing: A Documentation and Verification Reference for Procurement Teams

Retatrutide is a triple-receptor research peptide. Before sourcing it in bulk, procurement teams need identity confirmation by mass spectrometry, net content verification on the batch COA, and clarity on lyophilized cold-chain requirements. This reference covers what to confirm with a supplier before committing to an order.

What Retatrutide Is — and Why Its Receptor Profile Affects Sourcing Decisions

Retatrutide (Eli Lilly code: LY3437943) is a 39-amino-acid synthetic peptide that acts as a simultaneous agonist at three receptors: GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and the glucagon receptor (GcgR). This triple-receptor profile distinguishes it from dual agonists like tirzepatide (GLP-1R + GIPR) and single agonists like semaglutide (GLP-1R only, 31 amino acids). For a detailed comparison of these receptor classes and their structural differences, see our GLP-1 peptide classes reference.

As an investigational compound, retatrutide is not approved for clinical use and is sourced exclusively for research purposes. That status has direct implications for procurement:

• Supplier access is narrower than for more established research peptides.
• Regulatory history and third-party testing documentation are thinner across the market — which makes batch-level verification more important, not less.
• Buyers have fewer published reference points for evaluating COA claims, so understanding what good documentation looks like matters before you issue an RFQ.

Retatrutide is a synthetic 39-amino-acid research peptide and triple agonist at GLP-1R, GIPR, and the glucagon receptor (GcgR). It is an investigational compound, not approved for clinical use, and is supplied for research purposes only.

Documentation to Request Before Confirming a Retatrutide Supplier

The single most consistent differentiator between reliable retatrutide suppliers and unreliable ones is documentation quality — not price. A supplier who provides batch-specific reports with verifiable data is a fundamentally different counterparty from one who offers only a generic "COA available on request."

Request these documents before placing any order:

Certificate of Analysis (COA)

The COA should include:

• Purity by HPLC — expressed as a percentage, with the analytical method specified (reverse-phase HPLC, gradient conditions)
• Identity confirmation method — mass spectrometry (ESI-TOF or LC-MS), not just "confirmed by HPLC"
• Net peptide content — the actual milligrams of active peptide per vial or per gram, after accounting for water and counterion (typically TFA or acetate)
• Water content — determined by Karl Fischer titration or loss on drying
• Counterion content — TFA or acetate, depending on synthesis and purification method
• Batch number and manufacture/test date
• Testing laboratory — named, with contact details; third-party testing carries significantly more weight than in-house COAs

For a full breakdown of how to read each section of a peptide COA alongside HPLC and mass spectrometry reports, see reading a peptide COA and HPLC report.

HPLC Chromatogram (Original File, Not a Screenshot)

The chromatogram shows the peak profile for the batch. Request the actual report file. Key items to verify: the main peptide peak accounts for the stated purity percentage, no major unlabeled peaks are present, and the method details (column, mobile phase, gradient) are specified.

Mass Spectrometry Report

For a 39-amino-acid peptide like retatrutide, confirm that the molecular ion peak in the MS report corresponds to the known molecular weight for the compound. Charge states in ESI-MS are expected — the report should identify which charge state corresponds to which peak. Any supplier who cannot provide a batch-specific MS report for retatrutide should be asked why before the conversation continues.

Safety Data Sheet (SDS)

Required for import documentation in most jurisdictions, and useful for confirming how the supplier has classified the material for handling and transport.

Purity Percentage Alone Is Not Enough

This is the most commonly misunderstood point in peptide procurement: a COA showing "99% purity by HPLC" does not tell you how many milligrams of active retatrutide are in the vial.

HPLC purity measures the fraction of UV-absorbing material in the sample that corresponds to the target peak. It does not account for water content or counterion. TFA (trifluoroacetic acid), commonly used in peptide synthesis and purification, adds mass without contributing any active peptide — and a batch with high TFA content can show 99% HPLC purity while containing significantly less net peptide than the label states.

The question to ask any supplier: What is the labeled fill amount, and what is the confirmed net peptide content per batch? A supplier who measures and discloses these separately is operating at a different standard from one who offers purity as a proxy for content. For the full explanation of how these measurements differ and what the gap means in practice, see purity percentage alone is not the same as net peptide content.

For retatrutide specifically — where batch availability is limited and the compound is not easily re-sourced — confirming net content before payment is not optional. It determines whether the labeled dose in the vial is what will actually be used in the research application.

Packaging and Cold-Chain Expectations for Lyophilized Retatrutide

Retatrutide for research supply is provided as a lyophilized (freeze-dried) powder, typically in sealed glass vials. Common fill amounts for research quantities are 1 mg, 2 mg, 5 mg, and 10 mg per vial; custom fills are available for larger B2B orders. Our retatrutide lyophilized peptide vial supply is offered in these formats, with batch-specific documentation available on request.

Storage Conditions

Lyophilized retatrutide is stable at ≤−20°C when sealed and kept away from moisture and light. For long-term archival storage beyond 12 months, −80°C is preferable. Once a vial is opened and the peptide reconstituted, avoid repeated freeze-thaw cycles — for research purposes, aliquoting reconstituted material before freezing is standard handling practice.

Shipping Requirements

For international shipments, confirm with the supplier:

• Whether dry ice is used and how transit time is managed relative to dry ice duration
• Whether temperature excursion documentation is provided
• How the material is classified for customs (research chemical / raw material)

Parameters to Specify in an RFQ

When issuing a request for quotation, be explicit about fill amount per vial, number of vials per shipment, labeling requirements (batch number, fill date, storage conditions on label), and whether labeled or unbranded packaging is needed. For a structured, ready-to-use checklist of the documentation and quotation parameters to confirm before ordering, see our retatrutide documentation and quotation checklist.

How to Assess a Retatrutide Supplier's Quality Documentation

Given how thin the verified-supplier landscape is for investigational compounds like retatrutide, documentation review is the primary due diligence tool available. A four-step framework:

1. Confirm the testing laboratory is named. A COA that says "third-party tested" without naming the lab is not third-party documentation. Established labs in the research peptide supply chain issue batch-specific reports with verifiable report numbers that can be independently confirmed.
2. Request the COA and chromatogram as original files. PDFs with embedded report data are harder to alter than image files; the metadata can also confirm when the analysis was run relative to the batch date.
3. Cross-check the MS peak against the known molecular structure. For a 39-amino-acid sequence, the expected monoisotopic mass and common ESI-MS charge states are calculable from the sequence. Any competent analytical reviewer — internal or third-party — can verify the reported peak against the theoretical value.
4. Confirm batch-level traceability. The batch number on the COA should match the vial label and the shipping documentation. Gaps in traceability are a due diligence concern regardless of how clean the analytical data looks.

For a broader checklist covering how to evaluate supplier documentation across peptide categories, see third-party supplier verification.